The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

Success with dostarlimab immunotherapy for uterine cancer with mismatch repair mutations

zsazsa1
zsazsa1 CSN Member Posts: 573 Member
in Uterine/Endometrial Cancer #1

https://www.nytimes.com/2025/04/27/health/cancer-immunotherapy-solid-tumors.html?unlocked_article_code=1.C08.fnfM.3jbPvxka1eGQ&smid=url-share

Free link to NYT article. It is showing excellent results in other solid tumors, too. It's approved for uterine cancer with mismatch repair mutations, and in trial for certain other tumors.

1Like Care

Comments

Discussion Boards